https://www.cnodes.ca/project/mncd/2026-02-13T11:25:01-0500monthly0.6 https://www.cnodes.ca/project/isotretinoin-update/2026-03-26T14:55:55-0400monthly0.6 https://www.cnodes.ca/project/intentional-self-harm-with-glp-1-receptor-agonists-for-diabetes/2024-11-14T12:48:49-0500monthly0.6 https://www.cnodes.ca/project/utilization-of-antidiabetic-drugs-during-pregnancy/2025-05-08T14:26:27-0400monthly0.6 https://www.cnodes.ca/project/pcsk9i-in-fh-feasibility-study/2026-02-13T11:26:12-0500monthly0.6 https://www.cnodes.ca/project/long-acting-inhalable-drugs-for-chronic-obstructive-pulmonary-disease/2026-02-13T11:26:33-0500monthly0.6 https://www.cnodes.ca/project/exploration-of-the-risk-of-suicidality-and-self-harm-with-glp-1-receptor-agonists-a-critical-appraisal/2024-11-20T09:00:10-0500monthly0.6 https://www.cnodes.ca/project/safety-monitoring-ozempic-diabetes/2026-01-22T14:38:25-0500monthly0.6 https://www.cnodes.ca/project/outpatient-nirmatrelvir-ritonavir-and-remdesivir-utilization-in-canada/2026-01-22T11:59:14-0500monthly0.6 https://www.cnodes.ca/project/opioid-use-and-diverticulitis/2025-02-12T13:23:13-0500monthly0.6 https://www.cnodes.ca/project/fluoroquinolones-drug-utilization-study-update/2026-04-10T09:18:16-0400monthly0.6 https://www.cnodes.ca/project/tofacitinib-and-uc-feasibility/2026-01-22T11:52:05-0500monthly0.6 https://www.cnodes.ca/project/the-use-of-atypical-antipsychotics-and-the-risk-of-breast-cancer-q10-04/2022-03-31T13:12:42-0400monthly0.6 https://www.cnodes.ca/project/the-use-of-atypical-antipsychotics-and-the-risk-of-breast-cancer/2022-03-29T18:12:36-0400monthly0.6 https://www.cnodes.ca/project/hydrochlorothiazide-and-risk-of-non-melanoma-skin-cancer-critical-appraisal/2024-01-26T15:18:26-0500monthly0.6 https://www.cnodes.ca/project/quetiapine-and-cardiomyopathy-q12-04/2022-03-31T17:09:36-0400monthly0.6 https://www.cnodes.ca/project/association-between-newer-antidepressants-and-persistent-pulmonary-hypertension-of-the-newborn-q12-10/2022-03-31T16:55:36-0400monthly0.6 https://www.cnodes.ca/project/reliability-of-covid-19-case-definitions-in-administrative-and-clinical-databases/2024-02-19T11:08:49-0500monthly0.6 https://www.cnodes.ca/project/corticosteroid-utilization-in-covid-19/2024-01-26T14:54:54-0500monthly0.6 https://www.cnodes.ca/project/cdm-coagulopathy-and-covid-19/2024-04-25T09:10:35-0400monthly0.6 https://www.cnodes.ca/project/doacs-doacs/2023-12-14T10:58:54-0500monthly0.6 https://www.cnodes.ca/project/methadone/2024-01-25T13:28:55-0500monthly0.6 https://www.cnodes.ca/project/multiple-imputation/2023-12-14T14:22:45-0500monthly0.6 https://www.cnodes.ca/project/extreme-restriction-design/2022-03-30T19:18:35-0400monthly0.6 https://www.cnodes.ca/project/weighted-estimation-for-confounded-binary-outcomes-subject-to-misclassification/2022-03-09T13:21:15-0500monthly0.6 https://www.cnodes.ca/project/use-of-systemic-oral-fluoroquinolones-in-canada/2021-12-01T13:16:05-0500monthly0.6 https://www.cnodes.ca/project/fluoroquinolone-use-and-acute-bacterial-sinusitis/2023-12-08T15:43:05-0500monthly0.6 https://www.cnodes.ca/project/fluoroquinolones-copd/2023-12-08T15:48:31-0500monthly0.6 https://www.cnodes.ca/project/fluoroquinolones-uti/2023-12-08T15:50:07-0500monthly0.6 https://www.cnodes.ca/project/validity-algorithm-cardiovascular-deaths/2023-12-14T11:01:37-0500monthly0.6 https://www.cnodes.ca/project/characteristics-of-new-users-of-newer-antidiabetic-drugs/2021-12-08T14:49:29-0500monthly0.6 https://www.cnodes.ca/project/cdm-arbs-utilization/2024-10-29T14:21:53-0400monthly0.6 https://www.cnodes.ca/project/domperidone-postpartum/2023-12-14T10:13:43-0500monthly0.6 https://www.cnodes.ca/project/hydrochlorothiazide-skin-cancer/2024-02-19T11:09:23-0500monthly0.6 https://www.cnodes.ca/project/sglt2-dka/2023-12-04T15:40:10-0500monthly0.6 https://www.cnodes.ca/project/sglt2-amputation/2023-12-04T15:38:00-0500monthly0.6 https://www.cnodes.ca/project/sglt2-uti/2023-12-04T15:33:56-0500monthly0.6 https://www.cnodes.ca/project/sglt2-mace/2023-12-14T11:05:20-0500monthly0.6 https://www.cnodes.ca/project/safety-of-bowel-cleansers-when-combined-with-bisacodyl-stimulant-laxative/2023-12-14T15:04:16-0500monthly0.6 https://www.cnodes.ca/project/prescription-patterns-of-ranitidine-in-canada/2024-10-31T11:03:54-0400monthly0.6 https://www.cnodes.ca/project/dispensing-opioids/2022-03-25T13:46:09-0400monthly0.6 https://www.cnodes.ca/project/pancreatic-cancer-validation/2023-12-14T11:13:10-0500monthly0.6 https://www.cnodes.ca/project/simulation-meta-analyses/2017-08-29T15:57:27-0400monthly0.6 https://www.cnodes.ca/project/conditional-caliper-matching/2017-08-29T15:04:27-0400monthly0.6 https://www.cnodes.ca/project/oxy-canada-usa/2022-03-25T13:46:06-0400monthly0.6 https://www.cnodes.ca/project/machine-learning-hdps/2022-03-28T09:02:13-0400monthly0.6 https://www.cnodes.ca/project/data-variability/2022-03-30T19:32:51-0400monthly0.6 https://www.cnodes.ca/project/extreme-cohort-restriction/2017-08-25T16:32:22-0400monthly0.6 https://www.cnodes.ca/project/emr-linkage/2017-08-31T14:54:29-0400monthly0.6 https://www.cnodes.ca/project/bayesian-stopping-rules/2017-08-25T16:08:29-0400monthly0.6 https://www.cnodes.ca/project/simulated-data-platform/2017-08-29T11:45:54-0400monthly0.6 https://www.cnodes.ca/project/tmle-pharmacoepi/2022-03-30T20:11:46-0400monthly0.6 https://www.cnodes.ca/project/inverse-probability-weights/2022-03-09T13:31:41-0500monthly0.6 https://www.cnodes.ca/project/hdps-unmeasured-confounders/2022-03-30T19:55:11-0400monthly0.6 https://www.cnodes.ca/project/effect-estimation-point-exposure/2022-03-09T13:33:19-0500monthly0.6 https://www.cnodes.ca/project/comparison-time-dependent-confounding/2022-03-28T11:14:12-0400monthly0.6 https://www.cnodes.ca/project/performance-different-propensity/2022-03-28T11:10:06-0400monthly0.6 https://www.cnodes.ca/project/confounding-effect-modification/2022-01-26T12:19:19-0500monthly0.6 https://www.cnodes.ca/project/marginal-confounder-prevalence/2022-03-28T12:37:24-0400monthly0.6 https://www.cnodes.ca/project/contour-plot-assessment/2022-03-28T12:33:45-0400monthly0.6 https://www.cnodes.ca/project/parallel-group-point-exposure/2022-03-28T12:19:27-0400monthly0.6 https://www.cnodes.ca/project/network-meta-analysis/2022-03-28T12:16:15-0400monthly0.6 https://www.cnodes.ca/project/confounding-drug-formulary-restriction/2022-03-28T11:44:17-0400monthly0.6 https://www.cnodes.ca/project/likelihood-ratio/2022-03-28T11:46:02-0400monthly0.6 https://www.cnodes.ca/project/head-to-head-comparison/2022-03-28T11:58:11-0400monthly0.6 https://www.cnodes.ca/project/observational-studies-drug-safety/2022-03-28T11:40:39-0400monthly0.6 https://www.cnodes.ca/project/ema-doacs/2024-01-29T15:30:15-0500monthly0.6 https://www.cnodes.ca/project/fluconazole/2025-01-08T09:54:07-0500monthly0.6 https://www.cnodes.ca/project/ondansetron/2024-02-07T11:46:33-0500monthly0.6 https://www.cnodes.ca/project/doacs-warfarin/2023-12-14T10:56:50-0500monthly0.6 https://www.cnodes.ca/project/doacs-vte/2022-03-25T13:24:57-0400monthly0.6 https://www.cnodes.ca/project/rheumatoid-arthritis/2024-01-25T13:49:56-0500monthly0.6 https://www.cnodes.ca/project/ppi-mi/2022-03-31T15:43:32-0400monthly0.6 https://www.cnodes.ca/project/antipsychotics-hyperglycemia/2022-03-25T13:57:48-0400monthly0.6 https://www.cnodes.ca/project/isotretinoin/2022-03-25T13:57:36-0400monthly0.6 https://www.cnodes.ca/project/ppi-cdifficile/2022-03-31T16:44:27-0400monthly0.6 https://www.cnodes.ca/project/statins-diabetes/2022-03-25T13:55:34-0400monthly0.6 https://www.cnodes.ca/project/snri-aki/2022-03-25T13:55:02-0400monthly0.6 https://www.cnodes.ca/project/incretins-heart-failure/2022-03-25T13:44:09-0400monthly0.6 https://www.cnodes.ca/project/incretins-pancreatitis/2022-03-25T13:44:39-0400monthly0.6 https://www.cnodes.ca/project/propensity-score-overfitting/2022-03-30T19:52:41-0400monthly0.6 https://www.cnodes.ca/project/statins-aki/2022-03-25T13:56:44-0400monthly0.6 https://www.cnodes.ca/project/ppi-pneumonia/2022-03-25T13:56:29-0400monthly0.6 https://www.cnodes.ca/project/domperidone-vte/2022-03-25T13:46:48-0400monthly0.6 https://www.cnodes.ca/project/incretin-pancreatic-cancer/2022-03-25T13:44:43-0400monthly0.6